Ognjan Skrobić1, Aleksandar Simić2, Nebojša Radovanović2, Nenad Ivanović2, Marjan Micev3, Predrag Peško2. 1. Department of Esophageal Surgery, Clinical Center of Serbia, School of Medicine, First Surgical University Hospital, University of Belgrade, Koste Todorovica St 6, Belgrade, 11 000, Serbia. skrobico@gmail.com. 2. Department of Esophageal Surgery, Clinical Center of Serbia, School of Medicine, First Surgical University Hospital, University of Belgrade, Koste Todorovica St 6, Belgrade, 11 000, Serbia. 3. Department of Digestive Pathology, Clinical Center of Serbia, School of Medicine, First Surgical University Hospital, University of Belgrade, Belgrade, Serbia.
Abstract
OBJECTIVE: HALO radiofrequency ablation (RFA) has been proven as safe and efficient in eradication of both non- and dysplastic Barrett's esophagus (BE). Definitive post-RFA treatment is yet to be determined. METHODS: RFA was performed in 56 patients with BE, 38 with intestinal metaplasia (IM) and 18 with low-grade dysplasia (LGD), and repeated in case of residual BE. Length of the BE was classified according to C&M criteria. Follow-up included regular upper GI endoscopies with biopsies 6 months, 1 and 2 years after the complete resolution of BE. Patients were divided into two groups regarding post-RFA treatment: those maintaining proton pump inhibitors (PPI) daily and those submitted to laparoscopic Nissen fundoplication (LNF) at least 3 months after BE eradication or synchronous with RFA. RESULTS: There were no perforations or strictures related to RFA. Complete endoscopic resolution of BE was observed in 83.92 % patients (86.84 % IM and 77.77 % LGD), in 25 that maintained PPI and 22 in whom LNF was done. In PPI group, 2-year follow-up revealed BE recurrence in biopsy samples in 20 % of patients, while in LNF group 9.1 % of patients had recurrent IM. In overall sample of patients, no difference was noted regarding the influence of post-RFA treatment (p < 0.423). LNF proved superiority over PPI treatment in patients with long-segment BE (cutoff C > 4 cm, p < 0.021). CONCLUSION: HALO RFA is a safe procedure, with high rate of success in complete eradication of BE in symptomatic GERD patients. LNF provides good protection for neosquamous epithelium and in selected group of patients could be offered as a first line of treatment after HALO RFA.
OBJECTIVE: HALO radiofrequency ablation (RFA) has been proven as safe and efficient in eradication of both non- and dysplastic Barrett's esophagus (BE). Definitive post-RFA treatment is yet to be determined. METHODS: RFA was performed in 56 patients with BE, 38 with intestinal metaplasia (IM) and 18 with low-grade dysplasia (LGD), and repeated in case of residual BE. Length of the BE was classified according to C&M criteria. Follow-up included regular upper GI endoscopies with biopsies 6 months, 1 and 2 years after the complete resolution of BE. Patients were divided into two groups regarding post-RFA treatment: those maintaining proton pump inhibitors (PPI) daily and those submitted to laparoscopic Nissen fundoplication (LNF) at least 3 months after BE eradication or synchronous with RFA. RESULTS: There were no perforations or strictures related to RFA. Complete endoscopic resolution of BE was observed in 83.92 % patients (86.84 % IM and 77.77 % LGD), in 25 that maintained PPI and 22 in whom LNF was done. In PPI group, 2-year follow-up revealed BE recurrence in biopsy samples in 20 % of patients, while in LNF group 9.1 % of patients had recurrent IM. In overall sample of patients, no difference was noted regarding the influence of post-RFA treatment (p < 0.423). LNF proved superiority over PPI treatment in patients with long-segment BE (cutoff C > 4 cm, p < 0.021). CONCLUSION: HALO RFA is a safe procedure, with high rate of success in complete eradication of BE in symptomatic GERDpatients. LNF provides good protection for neosquamous epithelium and in selected group of patients could be offered as a first line of treatment after HALO RFA.
Authors: M Frazzoni; E Savarino; M Manno; G Melotti; V G Mirante; A Mussetto; H Bertani; R Manta; R Conigliaro Journal: Aliment Pharmacol Ther Date: 2009-06-10 Impact factor: 8.171
Authors: K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman Journal: Gastroenterology Date: 2013-03-28 Impact factor: 22.682
Authors: Corey S Johnson; Brian E Louie; Aaron Wille; Christy M Dunst; Stephanie G Worrell; Steven R DeMeester; Jessica Reynolds; Joe Dixon; John C Lipham; Michal Lada; Jeffrey H Peters; Thomas J Watson; Alexander S Farivar; Ralph W Aye Journal: J Gastrointest Surg Date: 2015-03-05 Impact factor: 3.452
Authors: D E Fleischer; B F Overholt; V K Sharma; A Reymunde; M B Kimmey; R Chuttani; K J Chang; R Muthasamy; C J Lightdale; N Santiago; D K Pleskow; P J Dean; K K Wang Journal: Endoscopy Date: 2010-09-20 Impact factor: 10.093
Authors: Benjamin J Vaccaro; Susana Gonzalez; John M Poneros; Peter D Stevens; Kristina M Capiak; Charles J Lightdale; Julian A Abrams Journal: Dig Dis Sci Date: 2011-04-06 Impact factor: 3.199
Authors: Robert J Korst; Sobeida Santana-Joseph; John R Rutledge; Arthur Antler; Vivian Bethala; Anthony DeLillo; Donald Kutner; Benjamin E Lee; Haleh Pazwash; Robert H Pittman; Michael Rahmin; Mitchell Rubinoff Journal: J Thorac Cardiovasc Surg Date: 2012-12-06 Impact factor: 5.209
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Jon C Gould; Mark R Wendling; Brant K Oeschlager; Sumeet K Mittal; Srinadh Komanduri; Kyle A Perry; Sean Cleary; Susan Galandiuk; Daniel J Scott; P Marco Fisichella; Nicholas J Shaheen; Kelly R Haisley; John G Hunter Journal: J Gastrointest Surg Date: 2017-02-27 Impact factor: 3.452